Hacker News new | past | comments | ask | show | jobs | submit login

I don't care about Shkreli, I care about whether the practice is ethical.

There are plenty of pharma analysts who have used the same techniques who have medical degrees, have worked on clinical trial design at pharma companies, etc. They often aren't the names you see when pharma complains about people shorting their stocks because pharma only wants to point at the head of the hedge fund who has no life sciences expertise. They don't want the public to know about the dozen experts the hedge fund manager is paying to analyze the filings in order to challenge the filings and decide whether to short the stock.

No one complains if your analysis shows the molecule is great and you go long, it only becomes evil if your analysis shows the molecule is crap.




And if pharma analysts who have medical degrees want to analyze filings from these companies, great.

But the specific example is talking about Martin Shkreli doing this - a man whose formal education is a Bachelor of Business from CUNY.

And ethics have roots in motivations. Shkreli couldn't give two hoots whether the drugs had efficacy or not. He wanted them to fail approval only because of his position in the companies.




Consider applying for YC's Spring batch! Applications are open till Feb 11.

Guidelines | FAQ | Lists | API | Security | Legal | Apply to YC | Contact

Search: